Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis

Thrombosis and Haemostasis

Volumn 99, Issue 6, 2008, Pages 987-988

  George, James N ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; ENDOTHELIUM CELL; ENZYME ACTIVITY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REMISSION; RISK ASSESSMENT; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; AUTOANTIBODIES; CYTOKINES; DOWN-REGULATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR;

EID: 44949127957     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-05-0278     Document Type: Editorial

References (15)

1. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New Engl J Med 1998; 339: 1578-1584.
2. Tsai H-M, Lian ECY. Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New Engl J Med 1998; 339: 1585-1594.
3. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-1029.
4. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-713.
5. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
6. Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92: 121-124.
7. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
8. Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107: 3161-3166.
9. Chauhan AK, Walsh MT, Zhu G, et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008; 111: 3452-3457.
10. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS 13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
11. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-159.
12. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine 1981; 60: 413-428.
13. Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenia purpura, and other thrombotic microangiopathies and coagulopathies. In: Heptinstall's Pathology of the Kidney. Philadelphia: Lippincott Williams & Wilkins; 2007: 699-762.
14. Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103: 1305-1310.
15. George JN. Congenital thrombotic thrombocytopenic purpura: Lessons for recognition and management of rare syndromes. Pediatr Blood Cancer 2008; 50: 947-948.